Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Mout L, Moll JM, Chen M, de Morrée ES, de Ridder CMA, Gibson A, Stuurman D, Aghai A, Erkens-Schulze S, Mathijssen RHJ, Sparreboom A, de Wit R, Lolkema MP, van Weerden WM. Mout L, et al. Among authors: de morree es. Br J Cancer. 2020 Dec;123(12):1715-1719. doi: 10.1038/s41416-020-01105-y. Epub 2020 Sep 29. Br J Cancer. 2020. PMID: 32989230 Free PMC article.
Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.
van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM. van Soest RJ, et al. Among authors: de morree es. Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24. Eur J Cancer. 2013. PMID: 24200698
The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH; Dutch Uro-Oncology Studygroup (DUOS). van Soest RJ, et al. Among authors: de morree es. Eur J Cancer. 2015 Nov;51(17):2562-9. doi: 10.1016/j.ejca.2015.07.037. Epub 2015 Aug 13. Eur J Cancer. 2015. PMID: 26278646 Clinical Trial.
Association of Survival Benefit With Docetaxel in Prostate Cancer and Total Number of Cycles Administered: A Post Hoc Analysis of the Mainsail Study.
de Morrée ES, Vogelzang NJ, Petrylak DP, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, Ochoa de Olza M, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, Li JS, de Wit R. de Morrée ES, et al. JAMA Oncol. 2017 Jan 1;3(1):68-75. doi: 10.1001/jamaoncol.2016.3000. JAMA Oncol. 2017. PMID: 27560549 Clinical Trial.
Loss of SLCO1B3 drives taxane resistance in prostate cancer.
de Morrée ES, Böttcher R, van Soest RJ, Aghai A, de Ridder CM, Gibson AA, Mathijssen RH, Burger H, Wiemer EA, Sparreboom A, de Wit R, van Weerden WM. de Morrée ES, et al. Br J Cancer. 2016 Sep 6;115(6):674-81. doi: 10.1038/bjc.2016.251. Epub 2016 Aug 18. Br J Cancer. 2016. PMID: 27537383 Free PMC article.
Reply to Masaki Shiota and Akira Yokomizo's Letter to the Editor re: Robert J. van Soest, Ellen S. de Morrée, Charlotte F. Kweldam, et al. Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer. Eur Urol 2015;67:981-5.
van Soest RJ, de Morrée ES, Kweldam CF, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM. van Soest RJ, et al. Among authors: de morree es. Eur Urol. 2016 Mar;69(3):e43-4. doi: 10.1016/j.eururo.2015.07.024. Epub 2015 Jul 30. Eur Urol. 2016. PMID: 26233533 No abstract available.
Inter-patient variability in docetaxel pharmacokinetics: A review.
Nieuweboer AJ, de Morrée ES, de Graan AJ, Sparreboom A, de Wit R, Mathijssen RH. Nieuweboer AJ, et al. Among authors: de morree es. Cancer Treat Rev. 2015 Jul;41(7):605-13. doi: 10.1016/j.ctrv.2015.04.012. Epub 2015 May 7. Cancer Treat Rev. 2015. PMID: 25980322 Review.
11 results